NovaBridge Biosciences (NBP) Accounts Payables (2018 - 2026)

NovaBridge Biosciences (NBP) has reported Accounts Payables for 8 consecutive years, with $16.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accounts Payables rose 123.35% year-over-year to $16.8 million; the TTM figure through Dec 2025 stood at $16.8 million (up 123.35% YoY), while the FY2025 annual figure was $16.8 million, up 123.35% from the prior year.
• Accounts Payables rose to $16.8 million in Q4 2025 per NBP's latest filing, from $15.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $92.8 billion in Q4 2021 and bottomed at $6.5 million in Q2 2025.
• Historically, Accounts Payables has averaged $7.2 billion across 5 years, with a median of $16.8 million in 2025.
• Annual changes were most pronounced in 2021 — Accounts Payables soared 109616.73% — and 2022, when it slumped 99.89%.
• NovaBridge Biosciences' Accounts Payables stood at $92.8 billion in 2021, then sank by 99.89% to $99.3 million in 2022, then plunged by 49.99% to $49.7 million in 2023, then sank by 84.84% to $7.5 million in 2024, then jumped by 123.35% to $16.8 million in 2025.
• Business Quant data shows NBP's Accounts Payables at $16.8 million in Q4 2025, $15.2 million in Q3 2025, and $6.5 million in Q2 2025.